OALibJ  Vol.6 No.6 , June 2019
Response of HCV Yemeni Patients to Sofosbuvir/Ledipasvir in Combination with Ribavirin
Abstract: Objectives: To study the effectiveness and safety of ledipasvir-sofosbuvir plus ribavirin treatment in Yemeni patient with HCV infection. Design: Prospective study of sixty-five Yemeni patients confirmed with HCV infection during the period from January 2017 to April 2018. Setting: Gastrointestinal and liver diseases specialized center in Ibb city, Yemen. Subjects: Patients with proved HCV infection by PCR. Results: We collected 65 cases with HCV infection. They were 19 (29.2%) males and 46 (70.8) females with age ranged between 18 years and 70 years and the mean age was 47.98 ± 11.90 years. sixteen (24.6%) of them had compensated liver cirrhosis and the remainder were non-cirrhotic healthy individual. The early virological response reported in 100% of cases while the sustained virological response (SVR) reported in 90.8%. The reported side effects of our patients were fatigue in (24.6%), abdominal pain in (13.8%), diarrhea in (10.8%), insomnia in (9.2%), headache in (7.7%), and nausea/vomiting in (7.7%). Conclusion: The Sofosbuvir-ledipasvir plus Ribavirin treatment was highly effective and safe for the treatment of hepatitis C patients in Yemen.
Cite this paper: Kassim, A. , Alathwary, R. and Al-hogami, T. (2019) Response of HCV Yemeni Patients to Sofosbuvir/Ledipasvir in Combination with Ribavirin. Open Access Library Journal, 6, 1-9. doi: 10.4236/oalib.1105507.

[1]   James, S.D., Anna, S.F.L., Guadalupe, G.T. and Massimo, P. (2018) Sherlock’s Diseases of the Liver and Biliary System. 13th Edition, Vol. 1, John Wiley & Sons Ltd., Oxford, 436-459.

[2]   World Health Organization (2017) Global Hepatitis Report 2017.

[3]   The Global Burden of Hepatitis C Working Group (2004) Global Burden of Disease (GBD) for Hepatitis C. The Journal of Clinical Pharmacology, 44, 20-29.

[4]   Mohd Hanafiah, K., Groeger, J., Flaxman, A.D. and Wiersma, S.T. (2013) Global Epidemiology of Hepatitis C Virus Infection: New Estimates of Age-Specific Antibody to HCV Seroprevalence. Hepatology, 57, 1333-1342.

[5]   Petruzziello, A., Marigliano, S., Lo-quercio, G., Cozzolino, A. and Cacciapuoti, C. (2016) Global Epidemiology of Hepatitis C Virus Infection: An Up-Date of the Distribution and Circulation of Hepatitis C Virus Genotypes. World Journal of Gastroenterology, 22, 7824-7840.

[6]   Lavanchy, D. (2011) Evolving Epi-demiology of Hepatitis C Virus. Clinical Microbiology and Infection: The Official Publica-tion of the European Society of Clinical Microbiology and Infectious Diseases, 17, 107-115.

[7]   Desenclos, J.C. (2003) The Challenge of Hepatitis C Surveillance in Europe. Eurosurveillance, 8, 99-100.

[8]   Dennis, L.K., Stephen, L.H., Larry, J., Anthony, S.F., Dan, L.L. and Joseph, L. (2015) Harrison’s Principle of Internal Medicine. 19th Edition, Vol. 2, McGraw-Hill Education, New York, 2041-2052.

[9]   Rajesh, G. and Sadiq, A. (2012) Epidemiology of Viral Hepatitis B and C Infections in Ibb City, Yemen. Hepatitis Monthly, 12, 460-462.

[10]   Thursz, M. and Fontanet, A. (2014) HCV Transmission in Industrialized Countries and Re-source-Constrained Areas. Nature Reviews Gastroenterology & Hepatology, 11, 28-35.

[11]   Blach, S., Zeuzem, S., Manns, M., Altraif, I., Duberg, A.S., Muljono, D.H., et al. (2017) Global Prevalence and Genotype Distribution of Hepatitis C Virus Infection in 2015: A Modeling Study. The Lancet Gastroenterology & Hepatology, 2, 161-176.

[12]   Al-Shamahy, H.A. and Abdu, S.S.A. (2013) Genotyping of Hepatitis C Virus (HCV) in Infected Patients from Yemen. European Journal of Basic Medical Science, 3, 78-82.

[13]   Zoulim, F., Liang, T.J., Gerbes, A.L., et al. (2015) Hepatitis C Virus Treatment in the Real World: Optimizing Treatment and Access to Therapies. Gut, 64, 1824-1833.

[14]   Cheng, G., Tian, Y., Doehle, B., et al. (2016) In Vitro Antiviral Activity and Resistance Profile Characterization of the Hepatitis C Virus NS5A Inhibitor Ledipasvir. Antimicrobial Agents and Chemotherapy, 60, 1847-1853.

[15]   Gower, E., Estes, C., Blach, S., Razavi-Shearer, K. and Razavi, H. (2014) Global Epidemiology and Genotype Distribution of the Hepatitis C Virus Infection. Journal of Hepatology, 61, S45-S57.

[16]   Lam, A.M., Espiritu, C., Bansal, S., Micolochick Steuer, H.M., Niu, C., Zennou, V., Keilman, M., Zhu, Y., Lan, S., Otto, M.J. and Furman, P.A. (2012) Genotype and Subtype Profiling of PSI-7977 as a Nu-cleotide Inhibitor of Hepatitis C Virus. Antimicrobial Agents and Chemotherapy, 56, 3359-3368.

[17]   Nelson, D.R., Cooper, J.N., Lalezari, J.P., Lawitz, E., Pockros, P.J., et al. (2015) All-Oral 12-Week Treatment with Daclatasvir plus Sofosbuvir in Patients with Hepatitis C Virus Genotype 3 Infection: ALLY-3 Phase III Study. Hepatology, 61, 1127-1135.

[18]   Hosny, S., Abdel, R.Z., Eman, M., Zienab, Z., Hend, S., Sherin, A.A. and Mervat, A.A. (2016) Sofosbuvir plus Daclatasvir with Fixed versus Weight Adjusted Dose of Ribavirin for Treatment of HCV, Genotype 4 among Egyptian Patients. EC Gastroenterology and Digestive System, 1, 143-153.

[19]   European Association for the Study of the Liver (2018) EASL Recom-mendations on Treatment of Hepatitis C 2018. Journal of Hepatology, 69, 461-511.

[20]   Lavanchy, D. (2009) The Global Burden of Hepatitis C. Liver International, 29, 74-81.

[21]   Koff, R.S. (2014) Review Article: The Efficacy and Safety of Sofosbuvir, a Novel, Oral Nucleotide NS5B Polymer-ase Inhibitor, in the Treatment of Chronic Hepatitis C Virus infection. Alimentary Pharmacology & Therapeutics, 39, 478-487.

[22]   European Association for the Study of the Liver (2017) EASL Recommendations on Treatment of Hepatitis C 2016. Journal of Hepatology, 66, 153-194.

[23]   Basu, P., et al. (2015) Sofosbuvir and Ledipasvir versus Sofosbuvir and Simeprevir Combination Therapy in the Management of Acute Hepatitis C: A Randomized Open Label Prospective Clinical Pilot Study. SLAM C Study. AASLD 2015, San Francisco, 13-17 November 2015, 1-20.

[24]   Rajesh, N.G. and Sadiq, K.A. (2012) Seroprevalence and Risk Factors for Hepatitis C Virus Infection among General Population in Central Region of Yemen. Hepatitis Research and Treatment, 2012, Article ID: 689726.

[25]   Ali, A., Ahmad, H., Ali, I., Khan, S., Zaidi, G. and Idrees, M. (2010) Prevalence of Active Hepatitis C Virus Infection in District Mansehra Pakistan. Virology Journal, 7, 334.

[26]   Chen, S.L. and Morgan, T.R. (2006) The Natural History of Hepatitis C Virus, (HCV) Infection. International Journal Medical Science, 3, 47-52.

[27]   Erensoy, S. (2010) Burden and Prevention of Viral Hepatitis in Turkey, Istanbul, Turkey, November 12-13, 2009. Meeting News, 18, 2.

[28]   Kamal, S.M. (2008) Acute Hepatitis C: A Systematic Review. American Journal of Gastroenterology, 103, 1283-1297.

[29]   Feld, J.J., Alnoor, R., Stephen, D.S., et al. (2017) Ledipasvir-Sofosbuvir plus Ribavirin in Treatment-Naive Patients with Hepatitis C Virus Genotype 3 Infection: An Open-Label Study. Clinical Infectious Diseases, 65, 13-19.


[31]   Zubia, J., Yasir, W., Maryam, M. and Asghar, A.D. (2018) Effect of Sofosbuvir plus Ribavirin Therapy on Hepatitis C Patients in Pakistan: A Retrospective Study. Peer J, 6, e4853.

[32]   Hend, I.S., Karim, A., Sherif, R., Eman, M. and Gamal, E. (2018) Generic Sofosbuvir/Ledipasvir for Treatment of Na?ve, Non-Cirrhotic, Easy to Treat Patients with Chronic Hepatitis C Genotype 4: 8 vs. 12 Weeks of Treatment. Hepatitis Monthly, 18, e78777.

[33]   Shiha, G., Esmat, G., Hassany, M., Soliman, R., et al. (2019) Ledipasvir/Sofosbuvir with or without Ribavirin for 8 or 12 Weeks for the Treatment of HCV Genotype 4 Infection: Results from a Randomised Phase III Study in Egypt. Gut, 68, 721-728.

[34]   Waheed, Y. (2015) Effect of Interferon plus Ribavirin Therapy on Hepatitis C Virus Genotype 3 Patients from Pakistan: Treatment Response, Side Effects and Future Prospective. Asian Pacific Journal of Tropical Medicine, 8, 85-89.